Choose Your Country or Region

Deutenzalutamide

Name: Deutenzalutamide
Brand: Selleck Chemicals
SKU: E1502
Rating: 5 (1 reviews)

Synonyms: HC-1119, MDV3100

Catalog No.E1502 Purity:99.33%

Deutenzalutamide (HC-1119, MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. It can be used in a treatment of advanced prostate cancer.

Deutenzalutamide Chemical Structure

CAS No. 1443331-82-5

Purity & Quality Control

Batch: E150201 DMSO]93 mg/mL]false]Ethanol]8 mg/mL]false]Water]Insoluble]false Purity: 99.33%

99.33

Deutenzalutamide Related Products

Related Products	Galeterone EPI-001 Cyproterone Acetate 3,3'-Diindolylmethane Bavdegalutamide (ARV-110)	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I Exosome Secretion Related Compound Library Human Hormone Related Compound Library	Click to Expand

Signaling Pathway

Androgen Receptor Signaling Pathway

Biological Activity

Description

Deutenzalutamide (HC-1119, MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. It can be used in a treatment of advanced prostate cancer.

Targets

Androgen Receptor ^[1]

36 nM

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT04986176	Unknown status	COVID-19 Respiratory Infection	Applied Biology Inc.\|Hinova Pharmaceuticals Inc.	April 15 2022	Phase 3
NCT01901133	Completed	Pharmacokinetics of MDV3100\|Healthy Subjects\|Kidney Diseases	Astellas Pharma Europe B.V.\|Medivation Inc.\|Astellas Pharma Inc	October 2011	Phase 1
NCT01913379	Completed	Healthy Subjects\|Pharmacokinetics\|Drug-Drug Interaction	Astellas Pharma Europe B.V.\|Medivation Inc.\|Astellas Pharma Inc	August 2011	Phase 1
NCT01911715	Completed	Healthy Subjects\|Pharmacokinetics of MDV3100	Astellas Pharma Europe B.V.\|Medivation Inc.\|Astellas Pharma Inc	April 2011	Phase 1
NCT00510718	Completed	Prostate Cancer\|Hormone Refractory Prostate Cancer	Pfizer\|Astellas Pharma Inc\|Medivation LLC a wholly owned subsidiary of Pfizer Inc.	July 23 2007	Phase 1

References

[1] Tran C, et al. Science. 2009 May 8;324(5928):787-90.

Chemical Information & Solubility

Molecular Weight	467.46	Formula	C₂₁H₁₃D₃F₄N₄O₂S
CAS No.	1443331-82-5	SDF	Download Deutenzalutamide SDF
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 93 mg/mL ( (198.94 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 8 mg/mL

Water : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):